Evaluation of Efficacy and Tolerability of Hizentra®

This trial will evaluate subjects with Primary Immunodeficiency Disorder (PIDD) who are
currently self-infusing Vivaglobin therapy for at least six months prior to changing to
Hizentra® therapy. Following screening and enrollment, subjects will continue to self-infuse
Vivaglobin® for seven infusions and then be converted to subcutaneous Hizentra® treatment
which they will continue for the next 6 months. The study will determine if Hizentra®
provides improved subject satisfaction by Treatment Satisfaction Questionnaire for
Medication. Diaries related to the local site reactions, the number of infusion sites per
subject/per dose, volume of Hizentra® per site, duration of infusions, systemic side effects
of the new medication and dose on IgG levels and antibody titers, and local site reactions
with Hizentra®.

Inclusion Criteria:

- Subjects currently self-infusing with Vivaglobin® for at least six months prior to
enrollment.

- Diagnosis of antibody deficiency due to primary immune deficiency disease.

- Stable serum IgG levels of > 550 mg/dl while on Vivaglobin® based on two
determinations at least 8 weeks apart and obtained within 6 months of entry.

- Willing to sign consent and follow study schedule.

- 1 year to 75 years of age.

Exclusion Criteria:

- Evidence of acute systemic illness or infection at within four weeks of screening or
enrollment.

- Any serious grade 3 or greater toxicity at screening.

- History of bleeding or chronic skin disorders.

- Selective IgA deficiency in absence of other antibody deficiencies

- History of anaphylactic or severe systemic reaction to Vivaglobin.

- Pregnant or breastfeeding females.

- Use of systemic pre-medication prior to SCIG.

- Protein losing enteropathy or nephritic syndrome.

- Any condition that in the opinion of the investigator would interfere with the
conduct of the study.

- Subject or guardian unwilling to sign consent or adhere to study schedule.